AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33762239 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving information on current PSS guidelines (n=25)
Number of subjects: 75
Study 34818646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby intervention (listening to lullabies for 20 min once a day)
Number of subjects: 76
Study 34818646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lullaby intervention)
Number of subjects: 76
Study 33258033 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 158
Study 35331684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (500 μg)
Number of subjects: 2040
Study 35331684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2040
Study 35331684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 2040
Study 33915192 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 45
Study 33915192 — intervention group
Group type: COMPARATOR
Intervention: Epidural technique
Number of subjects: 45
Study 33616190 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session psychological intervention
Number of subjects: 60
Study 33616190 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual control group
Number of subjects: 60
Study 32961385 — intervention group
Group type: EXPERIMENTAL
Intervention: CycleGAN (deep learning-based domain transfer from UWFP to TFP)
Number of subjects: 1196
Study 33587549 — intervention group
Group type: EXPERIMENTAL
Intervention: mIER (4 × 3 wk of moderate energy restriction interspersed with 3 × 1 wk of energy balance)
Number of subjects: 61
Study 33587549 — intervention group
Group type: COMPARATOR
Intervention: mCER (12 wk of continuous moderate energy restriction)
Number of subjects: 61
Study 33587549 — intervention group
Group type: EXPERIMENTAL
Intervention: mIER
Number of subjects: 61
Study 33587549 — intervention group
Group type: COMPARATOR
Intervention: mCER
Number of subjects: 61
Study 36068183 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle bevel pointing downwards during insertion
Number of subjects: 35
Study 36068183 — intervention group
Group type: COMPARATOR
Intervention: Needle bevel pointing upwards during insertion
Number of subjects: 35
Study 33751659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian additive regression trees (BART) with mixed models
Number of subjects: 0
Study 33751659 — intervention group
Group type: EXPERIMENTAL
Intervention: mixedBART framework
Number of subjects: 0
Study 35534039 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 104
Study 35534039 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine
Number of subjects: 104
Study 35534039 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin and/or Erdosteine
Number of subjects: 104
Study 33472541 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 33472541 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 0
Study 33472541 — intervention group
Group type: COMPARATOR
Intervention: Various treatment effect estimation methods
Number of subjects: 0
Study 35982457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Care Professionals (dental therapists and dental nurses) visiting care homes every 6 months and monthly for the first 3 months, then three-monthly thereafter
Number of subjects: 280
Study 35982457 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 280
Study 34639644 — intervention group
Group type: EXPERIMENTAL
Intervention: WAT-based group exercise intervention for 14 weeks
Number of subjects: 40
Study 34639644 — intervention group
Group type: COMPARATOR
Intervention: Control group with similar physical training and all BCTs
Number of subjects: 40
Study 36477479 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention delivered on a web-based platform
Number of subjects: 4118
Study 36477479 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 4118
Study 34737364 — intervention group
Group type: COMPARATOR
Intervention: 5-hydroxytryptophan (5-HTP) supplementation
Number of subjects: 77
Study 34737364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) enriched diet
Number of subjects: 77
Study 32199123 — intervention group
Group type: COMPARATOR
Intervention: FBH+
Number of subjects: 69176
Study 32199123 — intervention group
Group type: EXPERIMENTAL
Intervention: FPH
Number of subjects: 69176
Study 33855814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PnR)
Number of subjects: 0
Study 33896224 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin treatment
Number of subjects: 20890
Study 33896224 — intervention group
Group type: COMPARATOR
Intervention: Non-GHD controls
Number of subjects: 20890
Study 33896224 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated GHD patients
Number of subjects: 20890
Study 32684325 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elastic taping
Number of subjects: 30
Study 32684325 — intervention group
Group type: COMPARATOR
Intervention: Placebo-taping
Number of subjects: 30
Study 32684325 — intervention group
Group type: COMPARATOR
Intervention: Comparison between non-elastic taping and placebo-taping
Number of subjects: 30
Study 34281849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OSK-0028 (0.25 μg/kg/h)
Number of subjects: 75
Study 34281849 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose OSK-0028 (0.5 μg/kg/h)
Number of subjects: 75
Study 34281849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 34281849 — intervention group
Group type: EXPERIMENTAL
Intervention: OSK-0028 (both doses)
Number of subjects: 75
Study 35200094 — intervention group
Group type: EXPERIMENTAL
Intervention: R3 (3 minutes of active recovery)
Number of subjects: 30
Study 35200094 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 (1 minute of active recovery)
Number of subjects: 30
Study 34498248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0
Study 34498248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32178811 — intervention group
Group type: EXPERIMENTAL
Intervention: High Stress/Low Coping
Number of subjects: 102
Study 32178811 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Stress/High Coping
Number of subjects: 102
Study 32178811 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiles overall
Number of subjects: 102
Study 36011519 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine‐delivered counseling and printed materials on diet and medication adherence
Number of subjects: 299
Study 36011519 — intervention group
Group type: COMPARATOR
Intervention: Control group (counseling on smoking and physical activity)
Number of subjects: 299
Study 33243231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐curricular nutrition and mathematics program (4–5 lessons over 1–4 weeks)
Number of subjects: 12
Study 33243231 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching quality assessment
Number of subjects: 12
Study 33243231 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation using teacher interviews and student focus groups
Number of subjects: 12
Study 34332557 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day monotherapy
Number of subjects: 30
Study 34332557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with allogeneic CD8 + CD56+ NKT cell infusions twice per month for 12 cycles
Number of subjects: 30
Study 32228462 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based intervention arm (patients and spouses receive four-weekly structured group education & training sessions and 2 months of weekly tailored behavior change boosters)
Number of subjects: 194
Study 32228462 — intervention group
Group type: COMPARATOR
Intervention: Individual-based control arm (only patients receive the interventions)
Number of subjects: 194
Study 34321338 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-frame reminders
Number of subjects: 22046
Study 34321338 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-frame reminders
Number of subjects: 22046
Study 34321338 — intervention group
Group type: EXPERIMENTAL
Intervention: Precommitment messages
Number of subjects: 22046
Study 34321338 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder for second vaccination
Number of subjects: 22046
Study 34321338 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22046
Study 33778831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulp revascularization
Number of subjects: 100
Study 33778831 — intervention group
Group type: COMPARATOR
Intervention: Apexification
Number of subjects: 100
Study 33778831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 35906331 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-density formula (HDF, 90 kcal/100 ml)
Number of subjects: 64
Study 35906331 — intervention group
Group type: COMPARATOR
Intervention: Standard-density formula (SDF, 67 kcal/100 ml)
Number of subjects: 64
Study 35906331 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-density formula (HDF)
Number of subjects: 64
Study 35906331 — intervention group
Group type: COMPARATOR
Intervention: Standard-density formula (SDF)
Number of subjects: 64
Study 32677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-focused nursing care
Number of subjects: 66
Study 32672570 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane‐umbilical cord (AM‐UC)
Number of subjects: 81
Study 32672570 — intervention group
Group type: COMPARATOR
Intervention: Pericardium patch grafts
Number of subjects: 81
Study 33040236 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 40
Study 33040236 — intervention group
Group type: COMPARATOR
Intervention: ONSTEP technique
Number of subjects: 40
Study 32268801 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus exercise
Number of subjects: 32
Study 32268801 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 32
Study 35906459 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-NOSE (using Cai tube)
Number of subjects: 60
Study 35612866 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg or 2.5 mg twice daily)
Number of subjects: 4581
Study 35612866 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4581
Study 35612866 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 4581
Study 35612866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4581
Study 36090717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropocollagen gel applied to the skin around the wound
Number of subjects: 97
Study 32240018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) supplementation
Number of subjects: 11
Study 32240018 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) as a placebo
Number of subjects: 11
Study 36170500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionic pancreas treatment with insulin aspart or insulin lispro
Number of subjects: 326
Study 36170500 — intervention group
Group type: COMPARATOR
Intervention: Standard care (any insulin-delivery method with unblinded, real-time continuous glucose monitoring)
Number of subjects: 326
Study 34570405 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending by volunteers for 6 months
Number of subjects: 16
Study 34570405 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 16
Study 34715388 — intervention group
Group type: COMPARATOR
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 52
Study 34715388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (PENG)
Number of subjects: 52
Study 34133739 — intervention group
Group type: EXPERIMENTAL
Intervention: Library members incubated in the presence of lead (promotes nonenzymatic cleavage of RNA)
Number of subjects: 0
Study 34133739 — intervention group
Group type: COMPARATOR
Intervention: Library members incubated in the absence of lead
Number of subjects: 0
Study 32627890 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO+ breathing air
Number of subjects: 30
Study 32627890 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO+ breathing 16% O2
Number of subjects: 30
Study 32627890 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO+ breathing 14% O2
Number of subjects: 30
Study 32627890 — intervention group
Group type: COMPARATOR
Intervention: PFO- breathing air
Number of subjects: 30
Study 32627890 — intervention group
Group type: COMPARATOR
Intervention: PFO- breathing 16% O2
Number of subjects: 30
Study 32627890 — intervention group
Group type: COMPARATOR
Intervention: PFO- breathing 14% O2
Number of subjects: 30
Study 32627890 — intervention group
Group type: COMPARATOR
Intervention: PFO+ and PFO- at all levels of hypoxia
Number of subjects: 30
Study 33517908 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Less-Healthy (2 healthier, 6 less-healthy)
Number of subjects: 417
Study 33517908 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Healthier (6 healthier, 2 less-healthy)
Number of subjects: 417
Study 33517908 — intervention group
Group type: COMPARATOR
Intervention: Equal (2 healthier, 2 less-healthy)
Number of subjects: 417
Study 32401385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg, once daily before breakfast for 8 weeks
Number of subjects: 232
Study 32401385 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg, once daily before breakfast for 8 weeks
Number of subjects: 232
Study 33055188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose eplerenone
Number of subjects: 30
Study 33055188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33764085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers sharing personal good news
Number of subjects: 141
Study 33764085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers sharing personal good news
Number of subjects: 141
Study 33764085 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived partner responsiveness
Number of subjects: 141
Study 33764085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers sharing about the child
Number of subjects: 141
Study 35000939 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Core Obturators (n = 40)
Number of subjects: 86
Study 35000939 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaCore Pink Obturators (n = 40)
Number of subjects: 86
Study 35000939 — intervention group
Group type: COMPARATOR
Intervention: Positive Control (nonobturated, n = 3)
Number of subjects: 86
Study 35000939 — intervention group
Group type: COMPARATOR
Intervention: Negative Control (nonobturated, n = 3)
Number of subjects: 86
Study 34880156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/d)
Number of subjects: 2040
Study 34880156 — intervention group
Group type: COMPARATOR
Intervention: Low-dose pitavastatin (1 mg/d)
Number of subjects: 2040
Study 32074302 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 0
Study 32074302 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive leg squat exercise
Number of subjects: 0
Study 32074302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined activity (WBVT + exercise)
Number of subjects: 0
Study 34449285 — intervention group
Group type: EXPERIMENTAL
Intervention: Active portable high-efficiency particulate air cleaners
Number of subjects: 116
Study 34449285 — intervention group
Group type: COMPARATOR
Intervention: Sham portable high-efficiency particulate air cleaners
Number of subjects: 116
Study 34218931 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt list intervention
Number of subjects: 446
Study 34218931 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 446
Study 32685540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford Happiness Inventory (OHI)
Number of subjects: 500
Study 34121344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose biologics
Number of subjects: 5352
Study 34121344 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic-switch
Number of subjects: 5352
Study 34121344 — intervention group
Group type: COMPARATOR
Intervention: No-change group
Number of subjects: 5352
Study 34642026 — intervention group
Group type: EXPERIMENTAL
Intervention: CP/ganitumab (18 mg/kg q3w)
Number of subjects: 170
Study 34642026 — intervention group
Group type: COMPARATOR
Intervention: CP/placebo
Number of subjects: 170
Study 34642026 — intervention group
Group type: EXPERIMENTAL
Intervention: CP/ganitumab
Number of subjects: 170
Study 34642026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab response
Number of subjects: 170
Study 33278625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin (12 mg once daily for 5 days)
Number of subjects: 72
Study 33278625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin + doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days)
Number of subjects: 72
Study 33278625 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 72
Study 33571035 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist-delivered FCR intervention
Number of subjects: 61
Study 34602110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or Sertraline treatment for 6 weeks
Number of subjects: 200
Study 34602110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 200
Study 34602110 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (Fluoxetine or Sertraline)
Number of subjects: 200
Study 34172394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily
Number of subjects: 59
Study 34172394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 32074597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Placement Matching (PCPM) guidelines
Number of subjects: 250
Study 32074597 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched aftercare
Number of subjects: 250
Study 32074597 — intervention group
Group type: EXPERIMENTAL
Intervention: Overmatched patients
Number of subjects: 250
Study 35699705 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily; n = 300)
Number of subjects: 500
Study 35699705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 200)
Number of subjects: 500
Study 33032795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation programme (4-week duration, including one 20-30 min face-to-face education session and 15-20 min telephone follow-ups twice per week)
Number of subjects: 82
Study 33032795 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient care
Number of subjects: 82
Study 35737078 — intervention group
Group type: EXPERIMENTAL
Intervention: IncoBoNT‐A 1:2.5 dilution (12 units)
Number of subjects: 15
Study 35737078 — intervention group
Group type: EXPERIMENTAL
Intervention: IncoBoNT‐A 1:5 dilution (6 units)
Number of subjects: 15
Study 35737078 — intervention group
Group type: EXPERIMENTAL
Intervention: IncoBoNT‐A 1:7.5 dilution (4 units)
Number of subjects: 15
Study 35737078 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 15
Study 35737078 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study 35737078 — intervention group
Group type: EXPERIMENTAL
Intervention: IncoBoNT‐A (all concentrations)
Number of subjects: 15
Study 32534967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid clinical-radiomics model
Number of subjects: 187
Study 32534967 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 187
Study 32534967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 187
Study 36151281 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative technique (ART)
Number of subjects: 11
Study 36151281 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative techniques
Number of subjects: 11
Study 36151281 — intervention group
Group type: COMPARATOR
Intervention: Direct restorative materials
Number of subjects: 11
Study 33787192 — intervention group
Group type: EXPERIMENTAL
Intervention: Zingiber officinale (Tablet Vomigone 500 mg II tds) and Echinacea (Tablet Rucoldup I tds) for seven days in addition to standard treatment (Hydroxychloroquine)
Number of subjects: 100
Study 33787192 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Hydroxychloroquine)
Number of subjects: 100
Study 34919861 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention (hygiene infrastructure improvements and hygiene promotion)
Number of subjects: 17457
Study 34919861 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed WASH intervention)
Number of subjects: 17457
Study 34919861 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention
Number of subjects: 17457
Study 34919861 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17457
Study 32063220 — intervention group
Group type: EXPERIMENTAL
Intervention: Retraining group (n = 340) underwent testing of PD knowledge and skills at 1, 3, 6, 12, 18, 24, 30, and 36 months after PD start.
Number of subjects: 671
Study 32063220 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 331) treated according to center routines.
Number of subjects: 671
Study 34325539 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 40
Study 34325539 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 40
Study 33594643 — intervention group
Group type: EXPERIMENTAL
Intervention: Garvan Fracture Risk Calculator
Number of subjects: 389
Study 33594643 — intervention group
Group type: EXPERIMENTAL
Intervention: POL-RISK algorithm
Number of subjects: 389
Study 33594643 — intervention group
Group type: COMPARATOR
Intervention: Thresholds at 8% and 13%
Number of subjects: 389
Study 32068531 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional brace
Number of subjects: 540
Study 32068531 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 540
Study 34378863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ergocalciferol (double dosage from K/DOQI guidelines) for 8 weeks
Number of subjects: 70